Glyco Property List
Pooled literature properties (glycanDB). Optional filters: ?dataset=uv_vis&property_key=...
GET /api/gdd/glyco-properties/?format=api&page=35
{ "count": 839, "next": "http://glycodata.org/api/gdd/glyco-properties/?format=api&page=36", "previous": "http://glycodata.org/api/gdd/glyco-properties/?format=api&page=34", "results": [ { "id": 681, "dataset": "heparin", "entity": "enoxaparin", "entity_group": "", "entity_class": "LMWH", "property": "disaccharide composition", "property_key": "disaccharide_composition", "value": "73.1", "unit": "%", "value_reported": "73.1", "unit_reported": "%", "method": "Experiment", "method_detail": "mol% of TriS disaccharide (UA2S-GlcNS6S) in enoxaparin, LC-MS disaccharide analysis", "conditions": "mol% of TriS disaccharide (UA2S-GlcNS6S) in enoxaparin, LC-MS disaccharide analysis", "conditions_detail": "mol% of TriS disaccharide (UA2S-GlcNS6S) in enoxaparin, LC-MS disaccharide analysis | unit id: TriS (UA2S-GlcNS6S) | source: porcine-derived LMWH", "doi": "10.1002/jps.23939", "source_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC3998821/", "year": "2014", "confidence": "high", "comments": "\"Enoxaparin...TriS...73.1 ± 0.2\" [Li Fu, Fuming Zhang, Guoyun Li, Akihiro Onishi, Ujjwal Bhaskar, Peilong Sun, Robert J. Linhardt, 2014, confidence: high]" }, { "id": 682, "dataset": "heparin", "entity": "enoxaparin", "entity_group": "", "entity_class": "LMWH", "property": "disaccharide composition", "property_key": "disaccharide_composition", "value": "15.2", "unit": "%", "value_reported": "15.2", "unit_reported": "%", "method": "Experiment", "method_detail": "mol% of NS6S disaccharide (UA-GlcNS6S) in enoxaparin, LC-MS disaccharide analysis", "conditions": "mol% of NS6S disaccharide (UA-GlcNS6S) in enoxaparin, LC-MS disaccharide analysis", "conditions_detail": "mol% of NS6S disaccharide (UA-GlcNS6S) in enoxaparin, LC-MS disaccharide analysis | unit id: NS6S (UA-GlcNS6S) | source: porcine-derived LMWH", "doi": "10.1002/jps.23939", "source_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC3998821/", "year": "2014", "confidence": "high", "comments": "\"Enoxaparin...ΔDi-NS6S...15.2 ± 0.9\" [Li Fu, Fuming Zhang, Guoyun Li, Akihiro Onishi, Ujjwal Bhaskar, Peilong Sun, Robert J. Linhardt, 2014, confidence: high]" }, { "id": 683, "dataset": "heparin", "entity": "LMWH-II (enzymatic ultrafiltration)", "entity_group": "", "entity_class": "LMWH", "property": "disaccharide composition", "property_key": "disaccharide_composition", "value": "76.8", "unit": "%", "value_reported": "76.8", "unit_reported": "%", "method": "Experiment", "method_detail": "mol% of TriS disaccharide (UA2S-GlcNS6S) in a new LMWH (LMWH-II) made by enzymatic ultrafiltration, LC-MS disaccharide analysis", "conditions": "mol% of TriS disaccharide (UA2S-GlcNS6S) in a new LMWH (LMWH-II) made by enzymatic ultrafiltration, LC-MS disaccharide analysis", "conditions_detail": "mol% of TriS disaccharide (UA2S-GlcNS6S) in a new LMWH (LMWH-II) made by enzymatic ultrafiltration, LC-MS disaccharide analysis | unit id: TriS (UA2S-GlcNS6S) | source: porcine-derived LMWH", "doi": "10.1002/jps.23939", "source_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC3998821/", "year": "2014", "confidence": "high", "comments": "\"LMWH-II...TriS...76.8 ± 0.1\" — TriS enriched relative to UFH [Li Fu, Fuming Zhang, Guoyun Li, Akihiro Onishi, Ujjwal Bhaskar, Peilong Sun, Robert J. Linhardt, 2014, confidence: high]" }, { "id": 684, "dataset": "heparin", "entity": "heparin (porcine intestinal)", "entity_group": "", "entity_class": "heparin (UFH)", "property": "disaccharide composition", "property_key": "disaccharide_composition", "value": "68", "unit": "%", "value_reported": "68", "unit_reported": "wt%", "method": "Experiment", "method_detail": "TriS content of porcine intestinal (PI) heparins reported as 67-69 wt/wt% (value entered as midpoint 68; range in quote/notes), LC-MS and HPLC-UV disaccharide analysis", "conditions": "TriS content of porcine intestinal (PI) heparins reported as 67-69 wt/wt% (value entered as midpoint 68; range in quote/notes), LC-MS and HPLC-UV disaccharide analysis", "conditions_detail": "TriS content of porcine intestinal (PI) heparins reported as 67-69 wt/wt% (value entered as midpoint 68; range in quote/notes), LC-MS and HPLC-UV disaccharide analysis | unit id: TriS (UA2S-GlcNS6S) | source: porcine intestinal | range wt pct: 67-69", "doi": "10.1177/1076029616643822", "source_url": "https://journals.sagepub.com/doi/full/10.1177/1076029616643822", "year": "2016", "confidence": "high", "comments": "\"The TriS content of the PI heparins was very similar at 67 to 69 wt/wt%.\" — Reported as a range 67-69 wt%; value field is the midpoint, exact range preserved in quote and conditions [Kalib St Ange, Akihiro Onishi, Li Fu, Xiaojun Sun, Lei Lin, Daisuke Mori, Fuming Zhang, Jonathan S. Dordick, Jawed Fareed, Debra Hoppensteadt, Walter Jeske, Robert J. Linhardt, 2016, confidence: high]" }, { "id": 685, "dataset": "heparin", "entity": "heparin (bovine lung)", "entity_group": "", "entity_class": "heparin (UFH)", "property": "disaccharide composition", "property_key": "disaccharide_composition", "value": "78.5", "unit": "%", "value_reported": "78.5", "unit_reported": "wt%", "method": "Experiment", "method_detail": "TriS content of bovine lung (BL) heparin reported as 70-87 wt/wt% (value entered as midpoint 78.5; range in quote/notes), LC-MS/HPLC-UV disaccharide analysis", "conditions": "TriS content of bovine lung (BL) heparin reported as 70-87 wt/wt% (value entered as midpoint 78.5; range in quote/notes), LC-MS/HPLC-UV disaccharide analysis", "conditions_detail": "TriS content of bovine lung (BL) heparin reported as 70-87 wt/wt% (value entered as midpoint 78.5; range in quote/notes), LC-MS/HPLC-UV disaccharide analysis | unit id: TriS (UA2S-GlcNS6S) | source: bovine lung | range wt pct: 70-87", "doi": "10.1177/1076029616643822", "source_url": "https://journals.sagepub.com/doi/full/10.1177/1076029616643822", "year": "2016", "confidence": "high", "comments": "\"The TriS content of BL heparin was quite high ranging from 70 to 87 wt/wt.\" — Range 70-87 wt%; value is midpoint, range preserved [Kalib St Ange, Akihiro Onishi, Li Fu, Xiaojun Sun, Lei Lin, Daisuke Mori, Fuming Zhang, Jonathan S. Dordick, Jawed Fareed, Debra Hoppensteadt, Walter Jeske, Robert J. Linhardt, 2016, confidence: high]" }, { "id": 686, "dataset": "heparin", "entity": "heparin (bovine intestinal)", "entity_group": "", "entity_class": "heparin (UFH)", "property": "disaccharide composition", "property_key": "disaccharide_composition", "value": "53.5", "unit": "%", "value_reported": "53.5", "unit_reported": "wt%", "method": "Experiment", "method_detail": "TriS content of bovine intestinal (BI) heparins reported as 51-56 wt/wt% (value entered as midpoint 53.5), LC-MS/HPLC-UV disaccharide analysis", "conditions": "TriS content of bovine intestinal (BI) heparins reported as 51-56 wt/wt% (value entered as midpoint 53.5), LC-MS/HPLC-UV disaccharide analysis", "conditions_detail": "TriS content of bovine intestinal (BI) heparins reported as 51-56 wt/wt% (value entered as midpoint 53.5), LC-MS/HPLC-UV disaccharide analysis | unit id: TriS (UA2S-GlcNS6S) | source: bovine intestinal | range wt pct: 51-56", "doi": "10.1177/1076029616643822", "source_url": "https://journals.sagepub.com/doi/full/10.1177/1076029616643822", "year": "2016", "confidence": "high", "comments": "\"The TriS content of BI heparins was quite low at 51 to 56 wt/wt%.\" — Bovine intestinal heparin has notably lower TriS than porcine intestinal or bovine lung [Kalib St Ange, Akihiro Onishi, Li Fu, Xiaojun Sun, Lei Lin, Daisuke Mori, Fuming Zhang, Jonathan S. Dordick, Jawed Fareed, Debra Hoppensteadt, Walter Jeske, Robert J. Linhardt, 2016, confidence: high]" }, { "id": 687, "dataset": "heparin", "entity": "heparin (bovine intestinal)", "entity_group": "", "entity_class": "heparin (UFH)", "property": "disaccharide composition", "property_key": "disaccharide_composition", "value": "23.5", "unit": "%", "value_reported": "23.5", "unit_reported": "wt%", "method": "Experiment", "method_detail": "NS2S content of bovine intestinal (BI) heparins reported as 15-32 wt/wt% (value entered as midpoint 23.5), LC-MS/HPLC-UV disaccharide analysis", "conditions": "NS2S content of bovine intestinal (BI) heparins reported as 15-32 wt/wt% (value entered as midpoint 23.5), LC-MS/HPLC-UV disaccharide analysis", "conditions_detail": "NS2S content of bovine intestinal (BI) heparins reported as 15-32 wt/wt% (value entered as midpoint 23.5), LC-MS/HPLC-UV disaccharide analysis | unit id: NS2S (UA2S-GlcNS) | source: bovine intestinal | range wt pct: 15-32", "doi": "10.1177/1076029616643822", "source_url": "https://journals.sagepub.com/doi/full/10.1177/1076029616643822", "year": "2016", "confidence": "high", "comments": "\"BI heparins showed considerable amount of NS2S content, 15 to 32 wt/wt%.\" — BI heparin enriched in NS2S relative to porcine; range 15-32 wt%, value is midpoint [Kalib St Ange, Akihiro Onishi, Li Fu, Xiaojun Sun, Lei Lin, Daisuke Mori, Fuming Zhang, Jonathan S. Dordick, Jawed Fareed, Debra Hoppensteadt, Walter Jeske, Robert J. Linhardt, 2016, confidence: high]" }, { "id": 688, "dataset": "heparin", "entity": "heparin (beef/bovine lung)", "entity_group": "", "entity_class": "heparin (UFH)", "property": "disaccharide composition", "property_key": "disaccharide_composition", "value": "85", "unit": "%", "value_reported": "85", "unit_reported": "%", "method": "Review", "method_detail": "Fraction of the trisulfated disaccharide IdoA(2S)-GlcNS(6S) in beef lung heparin (review statement)", "conditions": "Fraction of the trisulfated disaccharide IdoA(2S)-GlcNS(6S) in beef lung heparin (review statement)", "conditions_detail": "Fraction of the trisulfated disaccharide IdoA(2S)-GlcNS(6S) in beef lung heparin (review statement) | unit id: TriS / IdoA(2S)-GlcNS(6S) | source: beef lung", "doi": "", "source_url": "https://en.wikipedia.org/wiki/Heparan_sulfate", "year": "2024", "confidence": "medium", "comments": "\"IdoA(2S)-GlcNS(6S) makes up 85% of heparins from beef lung\" — Tertiary/review source; classic textbook contrast value [Wikipedia contributors, 2024, confidence: medium]" }, { "id": 689, "dataset": "heparin", "entity": "heparin (porcine intestinal mucosa)", "entity_group": "", "entity_class": "heparin (UFH)", "property": "disaccharide composition", "property_key": "disaccharide_composition", "value": "75", "unit": "%", "value_reported": "75", "unit_reported": "%", "method": "Review", "method_detail": "Fraction of the trisulfated disaccharide IdoA(2S)-GlcNS(6S) in porcine intestinal mucosa heparin (review statement)", "conditions": "Fraction of the trisulfated disaccharide IdoA(2S)-GlcNS(6S) in porcine intestinal mucosa heparin (review statement)", "conditions_detail": "Fraction of the trisulfated disaccharide IdoA(2S)-GlcNS(6S) in porcine intestinal mucosa heparin (review statement) | unit id: TriS / IdoA(2S)-GlcNS(6S) | source: porcine intestinal mucosa", "doi": "", "source_url": "https://en.wikipedia.org/wiki/Heparan_sulfate", "year": "2024", "confidence": "medium", "comments": "\"about 75% of those from porcine intestinal mucosa\" — Tertiary/review source; classic ~75% porcine vs 85% beef-lung contrast [Wikipedia contributors, 2024, confidence: medium]" }, { "id": 690, "dataset": "heparin", "entity": "heparan sulfate (general)", "entity_group": "", "entity_class": "heparan sulfate", "property": "disaccharide composition", "property_key": "disaccharide_composition", "value": "50", "unit": "%", "value_reported": "50", "unit_reported": "%", "method": "Review", "method_detail": "The most common HS disaccharide GlcA-GlcNAc (N-acetylated, unsulfated) typically makes up ~50% of total (review statement) - contrast with the trisulfated-dominant heparin", "conditions": "The most common HS disaccharide GlcA-GlcNAc (N-acetylated, unsulfated) typically makes up ~50% of total (review statement) - contrast with the trisulfated-dominant heparin", "conditions_detail": "The most common HS disaccharide GlcA-GlcNAc (N-acetylated, unsulfated) typically makes up ~50% of total (review statement) - contrast with the trisulfated-dominant heparin | unit id: NA / unsulfated (GlcA-GlcNAc) | source: general heparan sulfate", "doi": "", "source_url": "https://en.wikipedia.org/wiki/Heparan_sulfate", "year": "2024", "confidence": "medium", "comments": "\"The most common disaccharide unit within heparan sulfate is composed of a glucuronic acid (GlcA) linked to N-acetylglucosamine (GlcNAc), typically making up around 50% of the total\" — Key contrast: HS is dominated by unsulfated N-acetylated disaccharide (~50%), opposite of heparin (trisulfated-dominant) [Wikipedia contributors, 2024, confidence: medium]" }, { "id": 691, "dataset": "heparin", "entity": "heparan sulfate (human serum, platelet-poor)", "entity_group": "", "entity_class": "heparan sulfate", "property": "disaccharide composition", "property_key": "disaccharide_composition", "value": "37.2", "unit": "%", "value_reported": "37.2", "unit_reported": "%", "method": "Experiment", "method_detail": "mol% of IV-A (UA-GlcNAc, unsulfated/N-acetylated) in HS/heparin-derived disaccharides from commercial platelet-poor human serum, LC-MS", "conditions": "mol% of IV-A (UA-GlcNAc, unsulfated/N-acetylated) in HS/heparin-derived disaccharides from commercial platelet-poor human serum, LC-MS", "conditions_detail": "mol% of IV-A (UA-GlcNAc, unsulfated/N-acetylated) in HS/heparin-derived disaccharides from commercial platelet-poor human serum, LC-MS | unit id: 0S / NA (UA-GlcNAc), IV-A | source: human serum (platelet poor)", "doi": "10.1021/ac2001077", "source_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC3094484/", "year": "2011", "confidence": "high", "comments": "\"37.2 ± 0.2\" — Unsulfated disaccharide is the most abundant - characteristic of HS, not heparin [Wei Wei, Milady R. Niñonuevo, Anish Sharma, Lieza M. Danan-Leon, Julie A. Leary, 2011, confidence: high]" }, { "id": 692, "dataset": "heparin", "entity": "heparan sulfate (human serum, platelet-poor)", "entity_group": "", "entity_class": "heparan sulfate", "property": "disaccharide composition", "property_key": "disaccharide_composition", "value": "14.6", "unit": "%", "value_reported": "14.6", "unit_reported": "%", "method": "Experiment", "method_detail": "mol% of IV-S (UA-GlcNS, NS) in HS/heparin-derived disaccharides from platelet-poor human serum, LC-MS", "conditions": "mol% of IV-S (UA-GlcNS, NS) in HS/heparin-derived disaccharides from platelet-poor human serum, LC-MS", "conditions_detail": "mol% of IV-S (UA-GlcNS, NS) in HS/heparin-derived disaccharides from platelet-poor human serum, LC-MS | unit id: NS (UA-GlcNS), IV-S | source: human serum (platelet poor)", "doi": "10.1021/ac2001077", "source_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC3094484/", "year": "2011", "confidence": "high", "comments": "\"14.6 ± 2.0\" [Wei Wei, Milady R. Niñonuevo, Anish Sharma, Lieza M. Danan-Leon, Julie A. Leary, 2011, confidence: high]" }, { "id": 693, "dataset": "heparin", "entity": "heparan sulfate (human serum, platelet-poor)", "entity_group": "", "entity_class": "heparan sulfate", "property": "disaccharide composition", "property_key": "disaccharide_composition", "value": "14.3", "unit": "%", "value_reported": "14.3", "unit_reported": "%", "method": "Experiment", "method_detail": "mol% of II-A (UA-GlcNAc6S, 6S) in HS/heparin-derived disaccharides from platelet-poor human serum, LC-MS", "conditions": "mol% of II-A (UA-GlcNAc6S, 6S) in HS/heparin-derived disaccharides from platelet-poor human serum, LC-MS", "conditions_detail": "mol% of II-A (UA-GlcNAc6S, 6S) in HS/heparin-derived disaccharides from platelet-poor human serum, LC-MS | unit id: 6S (UA-GlcNAc6S), II-A | source: human serum (platelet poor)", "doi": "10.1021/ac2001077", "source_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC3094484/", "year": "2011", "confidence": "high", "comments": "\"14.3 ± 1.0\" [Wei Wei, Milady R. Niñonuevo, Anish Sharma, Lieza M. Danan-Leon, Julie A. Leary, 2011, confidence: high]" }, { "id": 694, "dataset": "heparin", "entity": "heparan sulfate (human serum, platelet-poor)", "entity_group": "", "entity_class": "heparan sulfate", "property": "disaccharide composition", "property_key": "disaccharide_composition", "value": "5.9", "unit": "%", "value_reported": "5.9", "unit_reported": "%", "method": "Experiment", "method_detail": "mol% of I-S (UA2S-GlcNS6S, TriS) in HS/heparin-derived disaccharides from platelet-poor human serum, LC-MS", "conditions": "mol% of I-S (UA2S-GlcNS6S, TriS) in HS/heparin-derived disaccharides from platelet-poor human serum, LC-MS", "conditions_detail": "mol% of I-S (UA2S-GlcNS6S, TriS) in HS/heparin-derived disaccharides from platelet-poor human serum, LC-MS | unit id: TriS (UA2S-GlcNS6S), I-S | source: human serum (platelet poor)", "doi": "10.1021/ac2001077", "source_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC3094484/", "year": "2011", "confidence": "high", "comments": "\"5.9 ± 0.6\" — TriS is only ~6% in serum HS, vs ~65-85% in heparin - the central composition contrast [Wei Wei, Milady R. Niñonuevo, Anish Sharma, Lieza M. Danan-Leon, Julie A. Leary, 2011, confidence: high]" }, { "id": 695, "dataset": "heparin", "entity": "heparan sulfate (human serum, platelet-poor)", "entity_group": "", "entity_class": "heparan sulfate", "property": "disaccharide composition", "property_key": "disaccharide_composition", "value": "12.1", "unit": "%", "value_reported": "12.1", "unit_reported": "%", "method": "Experiment", "method_detail": "mol% of II-S (UA-GlcNS6S, NS6S) in HS/heparin-derived disaccharides from platelet-poor human serum, LC-MS", "conditions": "mol% of II-S (UA-GlcNS6S, NS6S) in HS/heparin-derived disaccharides from platelet-poor human serum, LC-MS", "conditions_detail": "mol% of II-S (UA-GlcNS6S, NS6S) in HS/heparin-derived disaccharides from platelet-poor human serum, LC-MS | unit id: NS6S (UA-GlcNS6S), II-S | source: human serum (platelet poor)", "doi": "10.1021/ac2001077", "source_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC3094484/", "year": "2011", "confidence": "high", "comments": "\"12.1 ± 2.1\" [Wei Wei, Milady R. Niñonuevo, Anish Sharma, Lieza M. Danan-Leon, Julie A. Leary, 2011, confidence: high]" }, { "id": 696, "dataset": "heparin", "entity": "heparan sulfate (human serum, male AB)", "entity_group": "", "entity_class": "heparan sulfate", "property": "disaccharide composition", "property_key": "disaccharide_composition", "value": "52.9", "unit": "%", "value_reported": "52.9", "unit_reported": "%", "method": "Experiment", "method_detail": "mol% of IV-A (UA-GlcNAc, unsulfated/N-acetylated) in HS/heparin-derived disaccharides from commercial male AB human serum, LC-MS", "conditions": "mol% of IV-A (UA-GlcNAc, unsulfated/N-acetylated) in HS/heparin-derived disaccharides from commercial male AB human serum, LC-MS", "conditions_detail": "mol% of IV-A (UA-GlcNAc, unsulfated/N-acetylated) in HS/heparin-derived disaccharides from commercial male AB human serum, LC-MS | unit id: 0S / NA (UA-GlcNAc), IV-A | source: human serum (male AB)", "doi": "10.1021/ac2001077", "source_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC3094484/", "year": "2011", "confidence": "high", "comments": "\"52.9 ± 1.7\" — Unsulfated N-acetylated dominant in serum HS [Wei Wei, Milady R. Niñonuevo, Anish Sharma, Lieza M. Danan-Leon, Julie A. Leary, 2011, confidence: high]" }, { "id": 697, "dataset": "heparin", "entity": "heparan sulfate (human serum, male AB)", "entity_group": "", "entity_class": "heparan sulfate", "property": "disaccharide composition", "property_key": "disaccharide_composition", "value": "0.5", "unit": "%", "value_reported": "0.5", "unit_reported": "%", "method": "Experiment", "method_detail": "mol% of I-S (UA2S-GlcNS6S, TriS) in HS/heparin-derived disaccharides from male AB human serum, LC-MS", "conditions": "mol% of I-S (UA2S-GlcNS6S, TriS) in HS/heparin-derived disaccharides from male AB human serum, LC-MS", "conditions_detail": "mol% of I-S (UA2S-GlcNS6S, TriS) in HS/heparin-derived disaccharides from male AB human serum, LC-MS | unit id: TriS (UA2S-GlcNS6S), I-S | source: human serum (male AB)", "doi": "10.1021/ac2001077", "source_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC3094484/", "year": "2011", "confidence": "high", "comments": "\"0.5 ± 0.2\" — TriS essentially absent in this serum HS sample [Wei Wei, Milady R. Niñonuevo, Anish Sharma, Lieza M. Danan-Leon, Julie A. Leary, 2011, confidence: high]" }, { "id": 698, "dataset": "heparin", "entity": "heparan sulfate (human serum, male AB)", "entity_group": "", "entity_class": "heparan sulfate", "property": "disaccharide composition", "property_key": "disaccharide_composition", "value": "10.5", "unit": "%", "value_reported": "10.5", "unit_reported": "%", "method": "Experiment", "method_detail": "mol% of III-S (UA2S-GlcNS, NS2S) in HS/heparin-derived disaccharides from male AB human serum, LC-MS", "conditions": "mol% of III-S (UA2S-GlcNS, NS2S) in HS/heparin-derived disaccharides from male AB human serum, LC-MS", "conditions_detail": "mol% of III-S (UA2S-GlcNS, NS2S) in HS/heparin-derived disaccharides from male AB human serum, LC-MS | unit id: NS2S (UA2S-GlcNS), III-S | source: human serum (male AB)", "doi": "10.1021/ac2001077", "source_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC3094484/", "year": "2011", "confidence": "high", "comments": "\"10.5 ± 2.1\" [Wei Wei, Milady R. Niñonuevo, Anish Sharma, Lieza M. Danan-Leon, Julie A. Leary, 2011, confidence: high]" }, { "id": 699, "dataset": "heparin", "entity": "heparan sulfate (human lung, donor m70)", "entity_group": "", "entity_class": "heparan sulfate", "property": "disaccharide composition", "property_key": "disaccharide_composition", "value": "70.7", "unit": "%", "value_reported": "70.7", "unit_reported": "%", "method": "Experiment", "method_detail": "Upper bound of TriS (UA2S-GlcNS6S) mol% across HS fractions from a 70-year-old male human lung; reported range 59.7-70.7%. Value is the stated upper bound; range in conditions/notes", "conditions": "Upper bound of TriS (UA2S-GlcNS6S) mol% across HS fractions from a 70-year-old male human lung; reported range 59.7-70.7%. Value is the stated upper bound; range in conditions/notes", "conditions_detail": "Upper bound of TriS (UA2S-GlcNS6S) mol% across HS fractions from a 70-year-old male human lung; reported range 59.7-70.7%. Value is the stated upper bound; range in conditions/notes | unit id: TriS (UA2S-GlcNS6S) | source: human lung (male, 70 y) | range pct: 59.7-70.7", "doi": "10.3390/molecules26185512", "source_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC8469465/", "year": "2021", "confidence": "medium", "comments": "\"UA2S-GlcNS6S: 59.7-70.7%\" — Unusually highly-sulfated lung HS approaching heparin-like TriS levels; reported as a range across fractions, value = upper bound [Derler, Kitic, Gerlza, Kungl, 2021, confidence: medium]" }, { "id": 700, "dataset": "heparin", "entity": "heparan sulfate (human lung, donor f92)", "entity_group": "", "entity_class": "heparan sulfate", "property": "disaccharide composition", "property_key": "disaccharide_composition", "value": "44.3", "unit": "%", "value_reported": "44.3", "unit_reported": "%", "method": "Experiment", "method_detail": "Upper bound of unsulfated UA-GlcNAc (NA/0S) mol% across HS fractions from a 92-year-old female human lung; reported range 27.7-44.3%. Value = stated upper bound; range in conditions/notes", "conditions": "Upper bound of unsulfated UA-GlcNAc (NA/0S) mol% across HS fractions from a 92-year-old female human lung; reported range 27.7-44.3%. Value = stated upper bound; range in conditions/notes", "conditions_detail": "Upper bound of unsulfated UA-GlcNAc (NA/0S) mol% across HS fractions from a 92-year-old female human lung; reported range 27.7-44.3%. Value = stated upper bound; range in conditions/notes | unit id: 0S / NA (UA-GlcNAc) | source: human lung (female, 92 y) | range pct: 27.7-44.3", "doi": "10.3390/molecules26185512", "source_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC8469465/", "year": "2021", "confidence": "medium", "comments": "\"UA-GlcNAc: 27.7-44.3%\" — More typical low-sulfation HS phenotype; high unsulfated content. Donor-to-donor HS heterogeneity is large [Derler, Kitic, Gerlza, Kungl, 2021, confidence: medium]" } ] }